-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Among several key mutant strains edited by WuXi AppTec's content team, the 501Y.
V2 mutant strain isolated for the first time in South Africa has attracted great attention in terms of vaccine efficacy.
On January 25, 2021, the mutant strain was isolated for the first time in China.
There are 10 amino acid mutation sites in the spike (S) protein, of which 5 are located in the N-terminal domain and 3 are located in the receptor binding domain (RBD) , 2 are located in the C-terminal domain.
How effective are the existing vaccines against this mutant strain? "The Lancet Microbe" recently published a study from a Chinese team that analyzed the neutralizing activity of two Chinese-developed vaccines against 501Y.
V2 mutant strains, including the inactivated vaccine BBIBP-CorV developed by Sinopharm Group.
The recombinant subunit vaccine ZF2001 developed by Hezhifeilongkoma.
Both vaccines have shown good immunogenicity in phase 1 and phase 2 clinical trials, and both have been conditionally approved for marketing/approved for emergency use in China.
Professor Yang Xiaoming of Beijing Institute of Biological Products Co.
, Ltd.
is the corresponding author of the paper, and many experts including Gao Fu, academician of the Chinese Academy of Sciences, jointly participated in the research.
Screenshot source: The Lancet Microbe research team collected 24 serum samples from subjects in two clinical trials, of which 12 received BBIBP-CorV vaccination and 12 received ZF2001 vaccination.
These subjects were all randomly selected To cover a series of serum samples with different neutralization titers.
The research team measured the neutralizing activity of these serum samples against the live new coronavirus strain GDPCC (501Y.
V2).
The wild-type virus strain HB02 and the virus strain BJ01 carrying the D614G mutation were used as controls.
The results showed that for the 501Y.
V2 mutant strain, all 24 serum samples from BBIBP-CorV or ZF2001 vaccinators retained the neutralizing effect to a large extent.
Compared with the neutralization effect on wild-type or D614G virus strain, the geometric mean titer (GMT) of 501Y.
V2 mutant strain is slightly lower.
For the serum of BBIBP-CorV vaccinators, GMT decreased from 110.
9 (95% CI 76.
7-160.
2) to 71.
5 (95% CI 51.
1-100.
1).
For the serum of ZF2001 vaccinators, GMT decreased from 106.
1 (95% CI 75.
0–150.
1) to 66.
6 (95% CI 51.
0–86.
9).
These findings indicate that for vaccines targeting the whole virus (BBIBP-CorV) or S protein RBD dimer (ZF2001), the 501Y.
V2 mutant strain failed to escape immune response, but considering that the neutralization titer may be reduced by 1.
5-1.
6 times , The clinical efficacy of these vaccines may have an impact.
The research team said that the serum samples of these two vaccines can neutralize the 501Y.
V2 and D614G mutant strains that are currently widely circulating around the world.
In the future, it is necessary to further study the difference in the neutralization efficiency of protein subunit vaccines (against true viruses) and mRNA vaccines (against pseudoviruses).
New crown research related reading The detailed data of the phase 3 trial of Kexing inactivated vaccines are announced, 100% prevention of moderate to severe COVID-19 NEJM: For the new coronavirus mutant, Sinopharm and Kexing inactivated vaccines have published the results of neutralization of the new crown vaccine for how long will it be “effective”? NEJM publishes mRNA vaccine protection persistence data JAMA: In response to key mutations of the new coronavirus, the vaccine protection effect is much higher than that of natural infection! Reduced 92% of COVID-19 infections and 94% of cases.
NEJM published data on Pfizer/BioNTech vaccines administered to 600,000 people in Israel.
Source: WuXi AppTec's content team drawing reference materials[1] Baoying Huang, et al.
, (2021).
Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.
V2.
The Lancet Microbe DOI: https://doi.
org/10.
1016/S2666-5247(21)00082-3 Note: This article aims to introduce medicine and health Research progress is not a treatment plan recommendation.
If you need guidance on treatment plans, please go to a regular hospital for treatment.
V2 mutant strain isolated for the first time in South Africa has attracted great attention in terms of vaccine efficacy.
On January 25, 2021, the mutant strain was isolated for the first time in China.
There are 10 amino acid mutation sites in the spike (S) protein, of which 5 are located in the N-terminal domain and 3 are located in the receptor binding domain (RBD) , 2 are located in the C-terminal domain.
How effective are the existing vaccines against this mutant strain? "The Lancet Microbe" recently published a study from a Chinese team that analyzed the neutralizing activity of two Chinese-developed vaccines against 501Y.
V2 mutant strains, including the inactivated vaccine BBIBP-CorV developed by Sinopharm Group.
The recombinant subunit vaccine ZF2001 developed by Hezhifeilongkoma.
Both vaccines have shown good immunogenicity in phase 1 and phase 2 clinical trials, and both have been conditionally approved for marketing/approved for emergency use in China.
Professor Yang Xiaoming of Beijing Institute of Biological Products Co.
, Ltd.
is the corresponding author of the paper, and many experts including Gao Fu, academician of the Chinese Academy of Sciences, jointly participated in the research.
Screenshot source: The Lancet Microbe research team collected 24 serum samples from subjects in two clinical trials, of which 12 received BBIBP-CorV vaccination and 12 received ZF2001 vaccination.
These subjects were all randomly selected To cover a series of serum samples with different neutralization titers.
The research team measured the neutralizing activity of these serum samples against the live new coronavirus strain GDPCC (501Y.
V2).
The wild-type virus strain HB02 and the virus strain BJ01 carrying the D614G mutation were used as controls.
The results showed that for the 501Y.
V2 mutant strain, all 24 serum samples from BBIBP-CorV or ZF2001 vaccinators retained the neutralizing effect to a large extent.
Compared with the neutralization effect on wild-type or D614G virus strain, the geometric mean titer (GMT) of 501Y.
V2 mutant strain is slightly lower.
For the serum of BBIBP-CorV vaccinators, GMT decreased from 110.
9 (95% CI 76.
7-160.
2) to 71.
5 (95% CI 51.
1-100.
1).
For the serum of ZF2001 vaccinators, GMT decreased from 106.
1 (95% CI 75.
0–150.
1) to 66.
6 (95% CI 51.
0–86.
9).
These findings indicate that for vaccines targeting the whole virus (BBIBP-CorV) or S protein RBD dimer (ZF2001), the 501Y.
V2 mutant strain failed to escape immune response, but considering that the neutralization titer may be reduced by 1.
5-1.
6 times , The clinical efficacy of these vaccines may have an impact.
The research team said that the serum samples of these two vaccines can neutralize the 501Y.
V2 and D614G mutant strains that are currently widely circulating around the world.
In the future, it is necessary to further study the difference in the neutralization efficiency of protein subunit vaccines (against true viruses) and mRNA vaccines (against pseudoviruses).
New crown research related reading The detailed data of the phase 3 trial of Kexing inactivated vaccines are announced, 100% prevention of moderate to severe COVID-19 NEJM: For the new coronavirus mutant, Sinopharm and Kexing inactivated vaccines have published the results of neutralization of the new crown vaccine for how long will it be “effective”? NEJM publishes mRNA vaccine protection persistence data JAMA: In response to key mutations of the new coronavirus, the vaccine protection effect is much higher than that of natural infection! Reduced 92% of COVID-19 infections and 94% of cases.
NEJM published data on Pfizer/BioNTech vaccines administered to 600,000 people in Israel.
Source: WuXi AppTec's content team drawing reference materials[1] Baoying Huang, et al.
, (2021).
Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.
V2.
The Lancet Microbe DOI: https://doi.
org/10.
1016/S2666-5247(21)00082-3 Note: This article aims to introduce medicine and health Research progress is not a treatment plan recommendation.
If you need guidance on treatment plans, please go to a regular hospital for treatment.
